European guidelines on cardiovascular disease prevention in clinical practice: Executive summary;Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: Versión resumida

Revista Espanola de Cardiologia

Volumn 61, Issue 1, 2008, Pages

  Graham, Ian ^c,e   Atar, Dan ^a,c   Borch Johnsen, Knut ^a,d   Boysen, Gudrun ^a   Burell, Gunilla ^a   Cifkova, Renata ^a   Dallongeville, Jean ^a,c   De Backer, Guy ^a,c   Ebrahim, Shah ^a,c   Gjelsvik, Bjørn ^a   Herrmann Lingen, Christoph ^a   Hoes, Arno ^a   Humphries, Steve ^a,c   Knapton, Mike ^a   Perk, Joep ^b,c   Priori, Silvia G ^a,c   Pyorala, Kalevi ^a,c   Reiner, Zeljko ^a   Ruilope, Luis ^a,c   Sans Menéndez, Susana ^a   Scholte Op Reimer, Wilma ^a,c   Weissberg, Peter ^a   Wood, David ^a,c   Yarnell, John ^a,c   Zamorano, José Luis ^a,c   more..

^a Uppsala ^*

^b National Archives of Sweden   (Sweden)

^c Asociación Europea para la Prevención Y Rehabilitació n Cardiovascular

^d Asociación Europea para el Estudio de la Diabetes

^e ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; WARFARIN;

ANTICOAGULATION; AORTA DISSECTING ANEURYSM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CORONARY ARTERY; DIABETES MELLITUS; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FAMILY HISTORY; GENOTYPE; HEART FAILURE; HEART PROTECTION; HEREDITY; HUMAN; LIPOPROTEIN DEFICIENCY; METABOLIC SYNDROME X; NUTRITION; OBESITY; PHARMACOGENETICS; PHENOTYPE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREDICTION; PROPHYLAXIS; REVIEW; RISK FACTOR; SCIENCE; TREATMENT INDICATION;

EID: 42449144309     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: None     Document Type: Review

References (230)

1. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and the European Society of Hypertension. Atherosclerosis. 1994;110:121-61.
2. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on coronary prevention. Eur Heart J. 1998;19:1434-503.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehab. 2003;10 Suppl 1:S1-78.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-87.
5. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.
6. www.ehnheart.org
7. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernández R, Gray A. European Cardiovascular Disease Statistics: 2005 edition. London: British Heart Foundation; 2005.
8. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610-9.
9. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J. 2006;27:107-13.
10. Tunstall-Pedoe H, Kulaasma K, Mahonen M, Tolonen H, Ruokokoski E. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10 year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 1999;353:1547-57.
11. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischemic heart disease in Finland. BMJ. 1994;309:23-7.
12. Pyörälä K, Lehto S, De Bacquer D, De Sutter J, Sans S, Keil U, et al; EUROASPIRE I Group; EUROASPIRE II Group. Risk factor management in diabetic and non-diabetic coronary heart disease patients. Findings from Euroaspire I and II surveys. Diabetologia. 2004;47:1257-65.
13. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-62.
14. Filipovic M, Goldacre MJ, Roberts SE, Yeates D, Duncan ME, Cook-Mozaffari P. Trends in mortality and hospital admission rates for abdominal aortic aneurysm in England and Wales, 1979-99. Br J Surg. 2005;92:968-75.
15. MASS: Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002;360:1531-9.
16. Kroger K, Stang A, Kondratieva H. Prevalence of peripheral arterial disease -results of the Heinz Nixdorf recall study. Eur J Epidemiol. 2006;21:279-85.
17. Price J, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20:344-53.
18. Hirsch A, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral artery disease. Circulation. 2006;113:e463-654.
19. Bhatt D, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-9.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
21. Henke P, Blackburn S, Proctor MC, Stevens J, Mukherjee D, Rajagopalin S, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medication: effect on graft patency, limb salvage, and mortality. J Vasc Surg. 2004;39:357-65.
22. Adams H, Bendixen PH, Kappelle LJ, Biller J, Long BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35-41.
23. European Stroke Initiative Executive Committee and the EUSI Writing Committee. European Stroke Initiative Recommendations for Stroke Management. Update 2003. Cerebrovasc Dis. 2003;16:311-37.
24. WHO Framework Convention on Tobacco Control (WHO FCTC). Disponible en: www.who.int/tobacco/framework/
25. Commission of the European Communities. Green paper. Promoting healthy diets and physical activity: a European dimension for the prevention of overweight, obesity and chronic diseases. Int J Epidemiol. 2005;14:COM 637.
26. Global Strategy on Diet, Physical Activity and Health. Geneva: WHO; 2004.
27. Clark A, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary heart disease. Ann Intern Med. 2005;143:659-72.
28. Mc Alister F, Lawson FME, Teo KK, Arsmtrogg PW. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ. 2001;323:957-62.
29. Sackett D, Richardson W, Rosenberg W, Haynes R. Evidence Based Medicine: How to Practice and Teach EBM. Edinburgh: Churchill-Livingstone; 1996.
30. McColl A, Smith H, White P, Field J. General practitioner's perceptions of the route to evidence based medicine: a questionnaire survey. BMJ. 1998;316:361-5.
31. Woolf S, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527-30.
32. Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ. 1998;317:858-61.
33. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490-7.
34. Davey-Smith G, Egger M. Who benefits from medical interventions? BMJ. 1994;308:72-4.
35. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ. 1998;316:140-4.
36. Hopper L, Ness A, Higgins JP, Moore T, Ebrahim S. GISSI-Prevenzione trial. Lancet. 1999;354:1557.
37. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading. BMJ. 1999;318:548-51.
38. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention programmes: a comparison of EUROASPIRE I & II in 9 countries. EUROASPIRE I & II Group. European Action on Secondary prevention by Intervention to Reduce Events. Lancet. 2001;357:995-1001.
39. EUROASPIRE Study Group: European Action on Secondary Prevention by Intervention to Reduce Events. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997;18:1569-82.
40. Rose G. The strategy of prevention: lessons from cardiovascular disease. BMJ. 1981;282:1847-51.
41. Anderson K, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-62.
42. Conroy R, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
43. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P. Cardiovascular risk factor changes in Finland I 1972-1997. Int J Epidemiol. 2000;29:49-56.
44. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med. 1996;156:745-52.
45. Dusseldorp E, Van Elderen T, Maes S, Meulman J, Kraaij V. A meta-analysis of psychoeduational programs for coronary heart disease patients. Health Psychol. 1999;18:506-19.
46. Blumenthal J, Sherwood A, Babyak MA, Watkins LL, Waugh R, Georgiades A, et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005;293:1626-34.
47. The health consequences of smoking: a report of the Surgeon General. Washington: US Department of Health and Human Services; 2004. Disponible en: www.surgeongeneral.gov/library/smokingconsequences/
48. Law M, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997;315:973-80.
49. The Health Benefits of Smoking Cessation. Washington: US Department of Health and Human Services; 1990.
50. McEwen A, Hajek P, McRobbic H, West R. Manual of Smoking Cessation. Oxford: Blackwell; 2006.
51. Barth J, Bengel J. Smoking cessation in patients with coronary heart disease: risk reduction and an evaluation of the efficacy of interventions. En: Jordan J, Barde B, Zeiher AM, editores. Contributions Toward Evidence-based Psychocardiology - A Systematic Review of the Literature. Washington: American Psychological Association; 2007. p. 83-105.
52. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.
53. Wajchenberg B. Subcutanuous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738.
54. Carr M, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89:2601-7.
55. Despres J, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoprotein, and cardiovascular disease. Arteriosclerosis. 1990;10:497-511.
56. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ. 1984;288:1401-11.
57. Folsom A, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong C-P, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med. 2000;160:2117-28.
58. World Health Organization Consultation of Obesity. Obesity: Preventing and Managing the Global Epidemic. Geneva: Division of Non-communicable Diseases, Programme of Nutrition, Family and Reproductive Health, WHO; 1998.
59. National Heart, Lung, and Blood Institute Obesity Education Initative Expert Panel. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Obes Res. 1998;6:S51-209.
60. Vikram N, Pandey RM, Misra A, Sharma R, Devi JR, Khanna N. Non-obese (body mass index < 25 kg/m2) Asian Indians with normal waist circumference have high cardiovascular risk. Nutrition. 2003;19:503-9.
61. Chowdbury B, Sjostrom L, Alpsten M, Kostanty J, Kvist H, Lofgren R. A multicompartment body composition technique based on computerized tomography. Int J Obes Relat Metab Disord. 1994;18:219-34.
62. Ross R, Leger L, Morris D, De Guise J, Guardo R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol. 1992;72:787-95.
63. Tornaghi G, Raiteri R, Pozzato C, Rispoli A, Bramani M, Cipolat M, et al. Anthropometric or ultrasonic measurements in assessment of visceral fat? A comparative study. Int J Obes Relat Metab Disord. 1994;18:771-5.
64. Armellini F, Zamboni M, Rigo L, Todesco T, Bergamo-Andreis IA, Procacci C, et al. The contribution of sonography to the measurement of intraabdominal fat. J Clin Ultrasound. 1990;18:563-7.
65. Pouliot M, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-8.
66. Petersson H, Daryani A, Riserus U. Sagittal abdominal diameter as a marker of inflammation and insulin resistance among immigrant women from the Middle East and native Swedish women: a cross-sectional study. Cardiovasc Diabetol. 2007;6:10.
67. Kvist H, Chowdhury B, Grangard U, Tylen U, Sjostrom L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr. 1988;48:1351-61.
68. Martinez-Gonzalez M, Martinez JA, Hu FB, Gibney MJ, Kearney J. Physical inactivity, sedentary lifestyle and obesity in the European Union. Int J Obes Relat Metab Disord. 1999;23:1192-201.
69. Rejeski W, Brawley LR, Ambrosius WT, Brubaker PH, Focht BC, Foy CG, et al. Older adults with chronic disease: benefits of group-mediated counseling in the promotion of physically active lifestyles. Health Physiol. 2003;22:414-23.
70. Carlson J, Norman GJ, Feltz DL, Franklin BA, Johnson JA, Locke SK. Self-efficacy, psychosocial factors, and exercise behavior in traditional versus modified cardiac rehabilitation. J Cardiopulm Rehab. 2001;21:363-73.
71. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004;110:2952-67.
72. Howard B, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:655-66.
73. Nordmann A, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:285-93.
74. Shaw K, O'Rourke P, Del Mar C, Kenardy J. Psychological Interventions for Overweight or Obesity (Cochrane Review). Oxford: Update Software; 2005.
75. Wing R, Tate DF, Gorin AA, Raynor HA, Fava JL. A self-regulation program for maintenance of weight loss. N Engl J Med. 2006;355:1563-71.
76. Rosengren A, Wilhelmsen L. Physical activity protects against coronary death and deaths from all causes in middle aged men. Evidence from a 20 year follow up of primary prevention study in Goteburg. Ann Epidemiol. 1997;7:69-7.
77. Paffenbarger R, Hyde RT, Wing AL, Lee IM, Jung DL, Kampret JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality amoung men. N Engl J Med. 1993;328:538-45.
78. Franco O, De Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med. 2005;165:2355-60.
79. Taylor R, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116:682-92.
80. Vanhees L, Lefevre J, Philippaerts R, Martens M, Huygens W, Troosters T, et al. How to assess physical activity? How to assess physical fitness. Eur J Cardiovasc Prev Rehab. 2005;12:102-14.
81. Börjesson M, Assanelli D, Carré F, Dugmore D, Panhuyzen-Goedkoop NM, Seiler C, et al; ESC Study Group of Sports Cardiology. Position Paper ESC Study Group of Sports Cardiology: recommendations for participation in leisure-time physical activity and competitive sports for patients with ischaemic heart disease. Eur J Cardiovasc Prev Rehab. 2006;13:137-49.
82. Kannel W, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489-94.
83. Diaz A, Bourassa M, Guertin M, Tardiff J. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967-74.
84. Levine H. Rest heart rate and life expectancy. J Am Coll Cardiol. 1997;30:1104-6.
85. Beere P, Glagov S, Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226:180-2.
86. Shaper A, Wannamethee G, Macfarlane P, Walker M. Heart rate, ischaemic heart disease and sudden death in middle-aged British men. Br Heart J. 1993;70:49-55.
87. Freemantle N, Cleland J, Young P, Mason J, Harrison J. b-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7.
88. Brophy J, Joseph L, Rouleau J. b-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med. 2001;134:550-60.
89. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:F43-9.
90. Tardif J, Ford I, Tendera M, Bourassa M, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529-36.
91. Kannel W. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-6.
92. Walker W, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992;268:3085-91.
93. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713-24.
94. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.
95. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-5.
96. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002;360:1903-13.
97. Vasan R, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682-6.
98. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
99. Staessen J, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-72.
100. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
101. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-98.
102. Zhang X, Attia J, D'Este C, Ma XY. The relationship between higher blood pressure and ischemic, haemorrhagic stroke among Chinese and Caucasians: meta-analyisis. Eur J Cardiovacular Prev Rehab. 2006;13:429-37.
103. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
104. Fox K, EURopean trial On reduction of cardiac events with Perindoprilin stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-8.
105. Nissen S, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-80.
106. HOPE: Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE substudy. Lancet. 2000;355:253-9.
107. Schrier R, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int. 2002;61:1086-97.
108. Atkins R, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281-7.
109. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370-9.
110. Casas J, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AR, et al. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026-33.
111. Otten J, Pitzi Helliwig J, Meyers LD. The Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington: National Academies Press; 2006.
112. Sacks F, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10.
113. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
114. Lindholm L, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-53.
115. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906.
116. Bradley H, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers a first line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24:2131-41.
117. Bonet S, Agusti A, Amau JM, Vidal X, Diogene E, Galve E, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621-7.
118. Heidenreich P, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927-36.
119. Sharma A, Pischon T, Hardt S, Kunz I, Luft FC. Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37:250-4.
120. Mancia G, Grassi G, Zancheti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3-10.
121. Lindholm L, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, et al; for the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-86.
122. Kjeldsen S, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, et al; VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:1405-12.
123. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, et al. Effects of metoprolol and carvedilol on preexisting and new on-set diabetes in patients with chronic heart failure data from the Carvedilol or metoprolol European Trial (COMET). Heart 2007 Jan 19 [Epub ahead of print].
124. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24:1397-403.
125. Klingbeil J, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-6.
126. Ciulla M, Paliotti R, Esposito A, Díez J, López B, Dahlöf B, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110:552-7.
127. Ciulla M, Paliotti R, Esposito A, Cuspidi C, Muiesan ML, Salvetti M, et al. Effects of the angiotension receptor antagonist candesartan and the ACE inhibitor enalapril on ultrasound markers of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy. J Hypertens. 2005;23 Suppl 2:S381.
128. GISEN, Gruppo Italiano di Studi Epidemiologici in Nefrologia. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-63.
129. Mann J, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, et al; HOPE Investigators. Progression of renal insufficiency in type2 diabetes with and without microalbuminuria: results of the Heart Out-comes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis. 2003;42:936-42.
130. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-51.
131. Brenner B, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
132. Lewis E, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
133. Lewis E, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62.
134. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, et al; European Lacidipine Study on Atherosclerosis investigators. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422-7.
135. Zanchetti A, Agabiti Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16:1667-76.
136. Borhani N, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 1996;276:785-91.
137. Ruilope L, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005;14:196-209.
138. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens. 1999;21:973-85.
139. Clement D, De Buyzere ML, De Bacquer DA, De Leeuw PW, Duprez DA, Fagard RH, et al; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-15.
140. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens. 1987;5:93-8.
141. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993;11:1133-7.
142. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation. 2000;102:1536-41.
143. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet. 1997;349:454-7.
144. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
145. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-16.
146. Colhoun H, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet. 2004;364:685-96.
147. 4S Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
148. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
149. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
150. Bucher H, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
151. Schwartz G, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-8.
152. Ray K, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al; PROVE IT-TIMI 22 Investigators. Early and late benefit of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE-IT-TIMI22 trial. J Am Coll Cardiol. 2005;46:1405-10.
153. De Lemos J, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndrome: phase Z of the A to Z trial. JAMA. 2004;292:1307-16.
154. Nissen S, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-65.
155. Reiner Z, Galic M, Hanzevacki M, Tedeschi-Reiner E. Concomitant use of statins and cytochrome P 450 inhibitors. Lijec Vjesn. 2005;127:65-8.
156. Grundy S, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of the metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-8.
157. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-97.
158. Alberti K, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-62.
159. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol. 2005;45:637-51.
160. Rees K, Bennett P, West R, Davey SG, Ebrahim S. Psychological Interventions for Coronary Heart Disease (Cochrane Review). Oxford: Update Software; 2004.
161. Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease - recommendations for clinical practice. Eur J Cardiovasc Prev Rehabil. 2004;11:75-9.
162. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-26.
163. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43.
164. Ridker P, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
165. Scarabin P, Arveiler D, Amouyel P, Dos Santos C, Evans A, Luc G, et al; Prospective Epidemiological Study of Myocardial Infarction. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME Study. Atherosclerosis. 2003;166:103-9.
166. Yarnell J, Patterson CC, Sweetnam PM, Lowe GDO. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J. 2004;25:1049-56.
167. Blankenberg S, Luc G, Ducimetière P, Arveiler D, Ferrières J, Amouyel P, et al; PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453-9.
168. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-8.
169. Pearson T, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;197:499-551.
170. Lowe G. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol. 2006;133:232-50.
171. Lowe G. Circulating inflammatory markers and risks of cardiovascular and noncardiovascular disease. J Thromb Haemostasis. 2005;3:1618-27.
172. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
173. Geelen A, Brouwer IA, Schouten EG, Maan AC, Katan MB, Zock PL. Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. Am J Clin Nutr. 2005;81:416-20.
174. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006;367:651-8.
175. Myers R, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120:963-9.
176. Hawe E, Talmud PJ, Miller GJ, Humphries SE. Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet. 2003;67:97-106.
177. Beekman M, Heijmans BT, Martin NG, Pedersen NL, Whitfield JB, DeFaire U, et al. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Res. 2002;5:87-97.
178. Austin M, Sandholzer C, Selby JV, Newman B, Krauss RM, Utermann G. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet. 1992;51:829-40.
179. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082-5.
180. Pankow J, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001;154:681-9.
181. Worns M, Victor A, Galle PR, Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels - a study in twins. Genes Immun. 2006;7:600-5.
182. Humphries S, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler Thromb Vasc Biol. 2004;24:628-36.
183. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature. 2006;444:444-54.
184. Casas J, Cooper J, Miller GJ, Hingorani AD, Humphries SE. Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. Ann Hum Genet. 2006;70:145-69.
185. Wilson P, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1997;97:1837-47.
186. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-5.
187. Cooper J, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181:93-100.
188. Yang Q, Khoury MJ, Friedman JM, Little J, Flanders WD. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol. 2005;34:1129-37.
189. Goldstein J, Brown M. Familial hypercholesterolaemia. En: Scriver C, Beaudet A, Sly W, Valle D, editores. The Metabolic Basis of Inherited Disease. New York: McGraw Hill; 1995. p. 1215-45.
190. Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet. 1972;1:393-9.
191. Scientific Steering Committee on behalf of Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303:893-6.
192. Williams R, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolaemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171-6.
193. Umans-Eckenhausen M, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165-8.
194. Heath K, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet. 2001;9:244-52.
195. Fouchier S, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet. 2001;109:602-15.
196. Holla O, Teie C, Berge KE, Leren TP. Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA. Clin Chim Acta. 2005;356:164-71.
197. Heath K, Gahan M, Whittall RA, Humphries SE. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis. 2001;154:243-6.
198. Myant N. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993;104:1-18.
199. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-6.
200. Familial hypercholesterolemia in Spain: case-finding program clinical genetic aspects. Semin Vasc Med. 2004;4:67-74.
201. Marks D, Thorogood M, Neil SM, Humphries SE, Neil HA. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen. 2006;13:156-9.
202. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol. 2003;23:335-8.
203. Leren T, Manshaus T, Skovholt U, Skodje T, Nossen IE, Teie C, et al. Application of molecular genetics for diagnosing familial hypercholesterolemiain Norway: results from a family-based screening program. Semin Vasc Med. 2004;4:75-85.
204. Hadfield S, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol. 2005;16:428-33.
205. Goldstein J, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest. 1973;52:1533-43.
206. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, et al. Familialcombined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet. 2004;36:371-6.
207. Naukkarinen J, Gentile M, Soro-Paavonen A, Saarela J, Koistinen HA, Pajukanta P, et al. USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet. 2005;14:2595-605.
208. Von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis. 2006;186:231-9.
209. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, et al. Cardiovascular disease in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006;27:994-1005.
210. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-93.
211. Manolio T, Pearson T, Wenger NH, Barrett-Connor E, Payne GH. Cholesterol and heart disease in older persons and women. Ann Epidemiol. 1992;2:161-76.
212. Jacobs A, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). Circulation. 1998;98:1279-85.
213. Stramba-Badiale M, Priori SG. Gender-specific prescription for cardiovascular diseases? Eur Heart J. 2005;26:1571-2.
214. Ridker P, Cook NR, Lee IM. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.
215. Kachelriess M, Kalender WA. Electrocardiogram-correlated image reconstruction from subsecond spiral computed tomography scans of the heart. Med Phys. 1998;25:2417-31.
216. Tedeschi-Reiner E, Reiner Z, Sonicki Z. Atherosclerosis of retinal arteries in men: Role of serum lipoproteins and apoproteins. Croat Med J. 2004;45:333-7.
217. Tedeschi-Reiner E, Strozzi M, Skoric B, Reiner Z. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. Am J Cardiol. 2005;96:1107-9.
218. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1:8-18.
219. Fox C, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844-50.
220. Sarafidis P, Whaley-Connell, Sowers J, Bakris GL. Cardiometabolic syndrome and chronic kidney disease: what is the link? JCMS. 2006;1:58-65.
221. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 2005;68:429-36.
222. Strippoli G, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized controlled trials. J Am Soc Nephrol. 2004;15:3154-65.
223. Segura J, Gracia-Donaire JA, Praga M, Ruilope LM. Chronic kidney disease as a situation of high added risk in hypertensive patients. J Am Soc Nephrol. 2006;17 Suppl 2:S136-40.
224. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy and outcomes in 6247 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-92.
225. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk people. BMJ. 2002;324:71-86.
226. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
227. Bonarjee V, Carstensen S, Caidahl K, Nilsen DW, Edner M, Berning J. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. Am J Cardiol. 1993;72:1004-9.
228. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Eng J Med. 2002;347:969-74.
229. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary. Eur Heart J. 2006;27:1979-2030.
230. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ. 2005;331:551.